Health Care

Insulet Corp’s shares fell as Medtronic and Tandem launch competitors, yet the company plans a 20‑22% Q1 revenue rise by expanding in Type 2 markets and new regions while addressing a $40 m recall of Omnipod 5 units.

CVS Health’s 2026 Stevie Awards in AI reveal how its data‑driven tools cut costs, boost PBM market share and forecast $75 M annual revenue lift, ahead of Walgreens and Walmart.

Novartis Q1 2024 earnings miss reveals generic pressure and pipeline promise – a deep dive into pricing, patent cliffs, M&A and future growth.

Merck’s acquisition of Terns Pharmaceuticals clears a key antitrust hurdle, potentially boosting its specialty drug portfolio and valuation while navigating Medicare reimbursement and breakthrough therapy benefits.

Intuitive Surgical’s Q1 2026 stock dip is a market correction, not a business crash—analysts still see upside from growing da Vinci 5 procedure volumes, but valuation and reimbursement shifts warrant careful monitoring.

WuXi AppTec Q1 2026 results show 30 % revenue jump, 26 % profit rise, and 70 % adjusted earnings boost, driving CDMO growth, cost savings, and investor confidence.

Barclays and Jyske Bank cut their target prices for Coloplast to DKK 500 and DKK 530, respectively, signalling a balanced outlook amid earnings expectations and market shifts in the medical‑device sector.

Otsuka Holdings’ Q1 earnings grow, while Taiho’s ARC‑02 ADC moves to Phase‑1 and Pharmavite leads bone‑health supplements—showing a balanced, growth‑oriented strategy across pharma and nutraceuticals.

Explore why Insmed Inc. ranks as a top upside‑potential holding in QQQ, with strong rare‑disease pipeline, growth outlook, and partnership prospects.

Humana partners with Cost Plus Drugs’ SwiftyRx to offer real‑time e‑Rx, mail‑order delivery and enhanced safety for members, boosting efficiency and adherence.